Comparison of bone mineral density of osteoporotic and osteopenia menopausal women treated with oral bisphosphonates before stopping the treatment and 1 year after drug holiday period.
Bisphosphonate
Bone mineral density
Osteopenia
Osteoporosis
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Apr 2024
Apr 2024
Historique:
received:
05
12
2023
accepted:
01
02
2024
revised:
29
01
2024
pubmed:
13
2
2024
medline:
13
2
2024
entrez:
12
2
2024
Statut:
ppublish
Résumé
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients' BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH. A total of 202 patients were selected with osteopenia (n = 95) and osteoporosis (n = 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device. The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (p = 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (p = 0.001). In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health. Key Points • The DH can reduce FN and LS T-scores • The BMD reduced after the DH period for both the osteoporosis and osteopenia groups • After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups.
Sections du résumé
BACKGROUND
BACKGROUND
Osteoporosis is a skeletal and bone disorder characterized by bone fractures and decreased bone mineral density (BMD). Bisphosphonates have a great tendency to bind to minerals, and their long-term use can increase the risk of bone fragility in patients. Stopping bisphosphonates after a period of time is called a drug holiday (DH). Recent evidence has shown that patients' BMD may decrease again during DH. However, few studies have been done in this regard. In the present study, we compared the BMD of postmenopausal women during bisphosphonates treatment and 1 year after DH.
MATERIAL AND METHODS
METHODS
A total of 202 patients were selected with osteopenia (n = 95) and osteoporosis (n = 107); they had been treated with alendronate for 5 years (a rheumatologist confirmed the diagnosis of osteopenia and osteoporosis) and had undergone DH for 1 year. At the arrival of all patients, BMD was checked with the DXA (dual-energy X-ray absorptiometry) method using the 2007 American Explorer model Hologic device based on the Caucasian race. One year later, patients were reassessed for BMD by the same device.
RESULT
RESULTS
The analysis of femoral neck (FN) and lumbar spine (LS) T-score indices in the osteopenia and the osteoporosis groups showed reduction after DH, and the difference was statistically significant in both groups (p = 0.001). After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups (p = 0.001).
CONCLUSION
CONCLUSIONS
In general, it can be said that DH can reduce FN and LS T-scores. The results indicated a significant reduction in BMD after the DH period for both the osteoporosis and osteopenia groups in the early months. Also, the effect of DH in osteoporosis patients was more compared to the osteopenia individuals, which could have implications for their treatment approach, and also its effect on bone health. Key Points • The DH can reduce FN and LS T-scores • The BMD reduced after the DH period for both the osteoporosis and osteopenia groups • After 1 year of stopping bisphosphonate treatment, the average of FN and LS BMD decreased in both groups.
Identifiants
pubmed: 38347325
doi: 10.1007/s10067-024-06906-7
pii: 10.1007/s10067-024-06906-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1375-1379Informations de copyright
© 2024. The Author(s), under exclusive licence to International League of Associations for Rheumatology (ILAR).
Références
Chen S, Zeng J, Huang L, Peng Y, Yan Z, Zhang A et al (2022) RNA adenosine modifications related to prognosis and immune infiltration in osteosarcoma. J Transl Med 20(1):228
doi: 10.1186/s12967-022-03415-6
pubmed: 35568866
pmcid: 9107650
Song Z-H, Xie W, Zhu S-Y, Pan J-J, Zhou L-Y, He C-Q (2018) Effects of PEMFs on Osx, Ocn, TRAP, and CTSK gene expression in postmenopausal osteoporosis model mice. Int J Clin Exp Pathol 11(3):1784
pubmed: 31938285
pmcid: 6958114
Ji MX, Yu Q (2015) Primary osteoporosis in postmenopausal women. Chronic Dis Transl Med 1(1):9–13
pubmed: 29062981
pmcid: 5643776
Chen S, Li Y, Zhi S, Ding Z, Huang Y, Wang W et al (2020) lncRNA Xist regulates osteoblast differentiation by sponging miR-19a-3p in aging-induced osteoporosis. Aging Dis 11(5):1058
doi: 10.14336/AD.2019.0724
pubmed: 33014522
pmcid: 7505278
Li J, Sun Y, Chen Z, Xie X, Gu F, Bi S et al (2022) Effects of bisphosphonates treatments in osteopenic older women: a systematic review and meta-analysis. Front Pharmacol 13:892091
doi: 10.3389/fphar.2022.892091
pubmed: 35662708
pmcid: 9160388
Zhang Y, Zhao C, Zhang H, Chen M, Meng Y, Pan Y et al (2023) Association between serum soluble α-klotho and bone mineral density (BMD) in middle-aged and older adults in the United States: a population-based cross-sectional study. Aging Clin Exp Res 35(10):2039–2049
doi: 10.1007/s40520-023-02483-y
pubmed: 37368163
Al-Helal B, Abdallah E, Asad R, Kassab M, Al Yousef A, Nessim G et al (2022) Assessment the efficacy and safety of denosumab use for treatment of osteoporosis in hemodialysis patients. J Ren Endocrinol 8:e21062
doi: 10.34172/jre.2022.21062
Karimifar M, Botlani N, Salari A (2020) A randomized clinical trial on improving osteopenia in postmenopausal women after two years of preventive treatment with alendronate; a dose of 35 mg per week is more effective or a dose of 70 mg? J Prev Epidemiol 5(1):e16-e
doi: 10.34172/jpe.2020.16
Khalili P, Maddah R, Maleknia M, Shateri Amiri B, Forouzani F, Hasanvand A et al (2023) Evaluation of genes and molecular pathways involved in the progression of monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma: a systems biology approach. Mol Biotechnol 65(8):1275–1286
doi: 10.1007/s12033-022-00634-6
pubmed: 36504354
Sanderson J, Martyn-St James M, Stevens J, Goka E, Wong R, Campbell F et al (2016) Clinical effectiveness of bisphosphonates for the prevention of fragility fractures: a systematic review and network meta-analysis. Bone 89:52–58
doi: 10.1016/j.bone.2016.05.013
pubmed: 27262775
Hayes KN, Winter EM, Cadarette SM, Burden AM (2021) Duration of bisphosphonate drug holidays in osteoporosis patients: a narrative review of the evidence and considerations for decision-making. J Clin Med 10(5):1140. https://doi.org/10.3390/jcm10051140
McClung MR (2016) Cancel the denosumab holiday. Osteoporos Int 27(5):1677–1682. https://doi.org/10.1007/s00198-016-3553-3
Sharafeddin F, Esfahan SZ, Keshavarz R, Goudarzi G (2024) Denosumab for osteoporosis in patients suffering from chronic kidney disease; a review on current data. Journal of Parathyroid Disease 12:e11242
doi: 10.34172/jpd.2023.11242
Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I et al (2017) Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas 101:23–30
doi: 10.1016/j.maturitas.2017.04.008
pubmed: 28539165
Chen Y, Xiang J, Wang Z, Xiao Y, Zhang D, Chen X et al (2015) Associations of bone mineral density with lean mass, fat mass, and dietary patterns in postmenopausal Chinese women: a 2-year prospective study. PLoS ONE 10(9):e0137097
doi: 10.1371/journal.pone.0137097
pubmed: 26335921
pmcid: 4559415
Bindon B, Adams W, Balasubramanian N, Sandhu J, Camacho P (2018) Osteoporotic fractures during bisphosphonate drug holiday. Endocr Pract 24(2):163–169
doi: 10.4158/EP171975.OR
pubmed: 29144808
Wang M, Wu YF, Girgis CM (2022) Bisphosphonate drug holidays: evidence from clinical trials and real-world studies. JBMR plus 6(6):e10629
doi: 10.1002/jbm4.10629
pubmed: 35720669
pmcid: 9189912
McNabb BL, Vittinghoff E, Schwartz AV, Eastell R, Bauer DC, Ensrud K et al (2013) BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res 28(6):1319–1327
doi: 10.1002/jbmr.1864
pubmed: 23408577
Mignot M, Taisne N, Legroux I, Cortet B, Paccou J (2017) Bisphosphonate drug holidays in postmenopausal osteoporosis: effect on clinical fracture risk. Osteoporos Int 28:3431–3438
doi: 10.1007/s00198-017-4215-9
pubmed: 28875236
Rutendo R, Farzahna M, Frederick R (2021) Impact of a bisphosphonate drug holiday on the bone mineral density in patients with osteoporosis. Wits J Clin Med 3(2):101–108
doi: 10.18772/26180197.2021.v3n2a2
Naylor K, Bradburn M, Paggiosi M, Gossiel F, Peel N, McCloskey E et al (2018) Effects of discontinuing oral bisphosphonate treatments for postmenopausal osteoporosis on bone turnover markers and bone density. Osteoporos Int 29:1407–1417
doi: 10.1007/s00198-018-4460-6
pubmed: 29525970